Dr. Ronald Z. Surowitz, D.O.
Family Medicine (Family Medicine Physician)
Medicare and federal program status
Opted out of Medicare from April 1, 2025 through April 1, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated March 17, 2025). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
FL license OS0003205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $30.59 in total to this clinician.
| GlaxoSmithKline, LLC. | $30.59 |
|---|
| Food and Beverage | $30.59 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 6 companies. The companies reported $4,036,554 in research payments for these studies, mostly to the institutions running them.
- Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presume…
Boehringer Ingelheim International GmbH - A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC. - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
ModernaTX, Inc. · Completed · NCT06060457 - The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
Seqirus USA Inc · Completed · NCT06015282
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.